The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Acq - P2P | Acquired

Total Raised


About Millennium Pharmaceuticals

Millennium Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts, that markets VELCADE, a cancer product, and has a clinical development pipeline of product candidates. Millennium research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, understanding of disease mechanisms and industrialized drug discovery platform, Millennium is developing a pipeline of product candidates.

Millennium Pharmaceuticals Headquarter Location

40 Landsdowne Street

Cambridge, Massachusetts, 02139,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Millennium Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Millennium Pharmaceuticals is included in 1 Expert Collection, including Cancer.



1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

Millennium Pharmaceuticals Patents

Millennium Pharmaceuticals has filed 372 patents.

The 3 most popular patent topics include:

  • Experimental cancer drugs
  • Transcription factors
  • Proteins
patents chart

Application Date

Grant Date


Related Topics




Experimental cancer drugs, Monoclonal antibodies, Antineoplastic drugs, Rare diseases, Orphan drugs


Application Date


Grant Date



Related Topics

Experimental cancer drugs, Monoclonal antibodies, Antineoplastic drugs, Rare diseases, Orphan drugs



Latest Millennium Pharmaceuticals News

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Shattuck Labs, Inc. of Class Action Lawsuit and Upcoming Deadline – STTK

Mar 31, 2022

Shattuck purports to be a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of cancer and autoimmune disease. The Company’s programs include SL-172154 (SIRPα-Fc-CD40L) and SL-279252 (PD1-Fc-OX40L). The Registration Statement emphasized the importance of Shattuck’s August 8, 2017 collaboration agreement (the “Collaboration Agreement”) with Millennium Pharmaceuticals, Inc., or Takeda, a wholly owned subsidiary of Takeda Pharmaceutical Company, Ltd. The complaint alleges that, in the Registration Statement and throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the Collaboration Agreement with Takeda was not solid; (2) Takeda and Shattuck would “mutually agree” to terminate the Collaboration Agreement in essentially one year; (3) as a result, Shattuck would cease to receive any future milestone, royalty, or other payments from Takeda; and (4) as a result, Defendants’ statements about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. On November 9, 2021, the Company issued a press release entitled “Shattuck Labs Reports Third Quarter 2021 Financial Results and Recent Business Highlights” which announced the termination of the Collaboration Agreement. On this news, Company’s share price fell $5.45 per share, or 28%, to close at $13.59 per share on November 9, 2021, on unusually heavy trading volume. Since the IPO, and as a result of the disclosure of material adverse facts omitted from the Company’s Registration Statement, Shattuck’s share price has fallen significantly below its IPO price, damaging Plaintiff and Class members. On February 10, 2022, the Company’s share price closed at $5.13 per share. Additionally, due to the materially deficient Registration Statement, Defendants have also violated their independent, affirmative duty to provide adequate disclosures about adverse conditions, risk and uncertainties. Item 303 of Securities and Exchange Commission Reg. S-K, 17 C.F.R. §229.303(a)(3)(ii) requires that the materials incorporated in a registration statement disclose all “known trends or uncertainties” reasonably expected to have a material unfavorable impact on the Company’s operations. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See . CONTACT:

  • When was Millennium Pharmaceuticals founded?

    Millennium Pharmaceuticals was founded in 1993.

  • Where is Millennium Pharmaceuticals's headquarters?

    Millennium Pharmaceuticals's headquarters is located at 40 Landsdowne Street, Cambridge.

  • What is Millennium Pharmaceuticals's latest funding round?

    Millennium Pharmaceuticals's latest funding round is Acq - P2P.

  • How much did Millennium Pharmaceuticals raise?

    Millennium Pharmaceuticals raised a total of $11.5M.

  • Who are the investors of Millennium Pharmaceuticals?

    Investors of Millennium Pharmaceuticals include Takeda Pharmaceutical, Mayfield, Venrock and Sofinnova Ventures.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.